

# Peter P Liu

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3840419/publications.pdf>

Version: 2024-02-01

56  
papers

7,633  
citations

185998

28  
h-index

155451

55  
g-index

61  
all docs

61  
docs citations

61  
times ranked

13460  
citing authors

#	ARTICLE	IF	CITATIONS
1	Features of Inflammatory Heart Reactions Following mRNA COVID-19 Vaccination at a Global Level. <i>Clinical Pharmacology and Therapeutics</i> , 2022, 111, 605-613.	2.3	25
2	A call to embrace a culture of openness in cardiovascular research. <i>European Heart Journal</i> , 2022, 43, 2261-2263.	1.0	3
3	The Social Robots Are Coming: Preparing for a New Wave of Virtual Care in Cardiovascular Medicine. <i>Circulation</i> , 2022, 145, 1291-1293.	1.6	2
4	Achieving Health Equities in Indigenous Peoples in Canada: Learnings Adaptable for Diverse Populations. <i>Circulation</i> , 2022, 146, 153-155.	1.6	3
5	Effect of anthracycline therapy on myocardial function and markers of fibrotic remodelling in childhood cancer survivors. <i>European Heart Journal Cardiovascular Imaging</i> , 2021, 22, 435-442.	0.5	19
6	Observational Cross-Sectional Study of Inflammatory Markers After Transient Ischemic Attacks, Acute Coronary Syndromes, and Vascular Stroke Events. <i>CJC Open</i> , 2021, 3, 675-679.	0.7	0
7	Pharmacological inhibition of arachidonate 12-lipoxygenase ameliorates myocardial ischemia-reperfusion injury in multiple species. <i>Cell Metabolism</i> , 2021, 33, 2059-2075.e10.	7.2	35
8	A small molecule targeting ALOX12-ACC1 ameliorates nonalcoholic steatohepatitis in mice and macaques. <i>Science Translational Medicine</i> , 2021, 13, eabg8116.	5.8	30
9	Multiple omics study identifies an interspecies conserved driver for nonalcoholic steatohepatitis. <i>Science Translational Medicine</i> , 2021, 13, eabg8117.	5.8	23
10	Biomarker discovery in cardiac allograft vasculopathy using targeted aptamer proteomics. <i>Clinical Transplantation</i> , 2020, 34, e13765.	0.8	16
11	Challenges in Cardiac and Pulmonary Sarcoidosis. <i>Journal of the American College of Cardiology</i> , 2020, 76, 1878-1901.	1.2	119
12	Time to Reframe Ejection Fraction in Light of New Pathophysiological Insights Into Heart Failure. <i>Journal of the American College of Cardiology</i> , 2020, 76, 1995-1998.	1.2	2
13	Redefining Cardiac Biomarkers in Predicting Mortality of Inpatients With COVID-19. <i>Hypertension</i> , 2020, 76, 1104-1112.	1.3	118
14	Sex-specific temporal trends in ambulatory heart failure incidence, mortality and hospitalisation in Ontario, Canada from 1994 to 2013: a population-based cohort study. <i>BMJ Open</i> , 2020, 10, e044126.	0.8	3
15	In-Hospital Use of Statins Is Associated with a Reduced Risk of Mortality among Individuals with COVID-19. <i>Cell Metabolism</i> , 2020, 32, 176-187.e4.	7.2	400
16	Response by Zhang et al to Letter Regarding Article, "Association of Inpatient Use of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers With Mortality Among Patients With Hypertension Hospitalized With COVID-19." <i>Circulation Research</i> , 2020, 126, e142-e143.	2.0	79
17	Comparative Impacts of ACE (Angiotensin-Converting Enzyme) Inhibitors Versus Angiotensin II Receptor Blockers on the Risk of COVID-19 Mortality. <i>Hypertension</i> , 2020, 76, e15-e17.	1.3	54
18	Association of Inpatient Use of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers With Mortality Among Patients With Hypertension Hospitalized With COVID-19. <i>Circulation Research</i> , 2020, 126, 1671-1681.	2.0	948

#	ARTICLE	IF	CITATIONS
19	The Science Underlying COVID-19. <i>Circulation</i> , 2020, 142, 68-78.	1.6	682
20	COVID-19 and the Heart. <i>JACC Basic To Translational Science</i> , 2020, 5, 884-887.	1.9	7
21	Diagnosing hypertension in Indigenous Canadians (<sc>DREAM</sc>â€œ<sc>GLOBAL</sc>): A randomized controlled trial to compare the effectiveness of short message service messaging for management of hypertension: Main results. <i>Journal of Clinical Hypertension</i> , 2019, 21, 29-36.	1.0	29
22	Myocarditis in the Setting of Cancer Therapeutics. <i>Circulation</i> , 2019, 140, 80-91.	1.6	278
23	Ethnic differences in acute heart failure outcomes in Ontario. <i>International Journal of Cardiology</i> , 2019, 291, 177-182.	0.8	9
24	Dilated cardiomyopathy. <i>Nature Reviews Disease Primers</i> , 2019, 5, 32.	18.1	347
25	Detailed phenotyping reveals distinct trajectories of cardiovascular function and symptoms with exposure to modern breast cancer therapy. <i>Cancer</i> , 2019, 125, 2762-2771.	2.0	10
26	Echocardiographic Assessment of Cardiac Function in Pediatric Survivors of Anthracycline-Treated Childhood Cancer. <i>Circulation: Cardiovascular Imaging</i> , 2019, 12, e008869.	1.3	33
27	Innate Immune Signaling and Its Role in Metabolic and Cardiovascular Diseases. <i>Physiological Reviews</i> , 2019, 99, 893-948.	13.1	57
28	Early Changes in Cardiovascular Biomarkers with Contemporary Thoracic Radiation Therapy for Breast Cancer, Lung Cancer, and Lymphoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2019, 103, 851-860.	0.4	53
29	Analysis of the Implementation, User Perspectives, and Feedback From a Mobile Health Intervention for Individuals Living With Hypertension (DREAM-GLOBAL): Mixed Methods Study. <i>JMIR MHealth and UHealth</i> , 2019, 7, e12639.	1.8	23
30	Wise Practices for Cultural Safety in Electronic Health Research and Clinical Trials With Indigenous People: Secondary Analysis of a Randomized Clinical Trial. <i>Journal of Medical Internet Research</i> , 2019, 21, e14203.	2.1	20
31	Utility of Novel Cardiorenal Biomarkers in the Prediction and Early Detection of Congestive Kidney Injury Following Cardiac Surgery. <i>Journal of Clinical Medicine</i> , 2018, 7, 540.	1.0	13
32	Disabilityâ€œfree survival after coronary artery bypass grafting in women and men with heart failure. <i>Open Heart</i> , 2018, 5, e000911.	0.9	25
33	Cardiovascular Magnetic Resonance in Nonischemicâ€œMyocardial Inflammation. <i>Journal of the American College of Cardiology</i> , 2018, 72, 3158-3176.	1.2	1,269
34	Prevalence and Longâ€œTerm Survival After Coronary Artery Bypass Grafting in Women and Men With Heart Failure and Preserved Versus Reduced Ejection Fraction. <i>Journal of the American Heart Association</i> , 2018, 7, .	1.6	42
35	The Cardiovascular Health in Ambulatory Care Research Team performance indicators for the primary prevention of cardiovascular disease: a modified Delphi panel study. <i>CMAJ Open</i> , 2017, 5, E315-E321.	1.1	9
36	N-Terminal Pro B-Type Natriuretic Peptide and High-Sensitivity Cardiac Troponin T Levels Are Related to the Extent of Hibernating Myocardium in Patients With Ischemic Heart Failure. <i>Canadian Journal of Cardiology</i> , 2017, 33, 1478-1488.	0.8	20

#	ARTICLE	IF	CITATIONS
37	A Framework for the Study of Complex mHealth Interventions in Diverse Cultural Settings. JMIR MHealth and UHealth, 2017, 5, e47.	1.8	45
38	The Effectiveness of Text Messaging for Detection and Management of Hypertension in Indigenous People in Canada: Protocol for a Randomized Controlled Trial. JMIR Research Protocols, 2017, 6, e244.	0.5	15
39	Long Noncoding RNAs in the Heart. Circulation: Cardiovascular Genetics, 2016, 9, 101-103.	5.1	11
40	Identifying Low-Abundance Biomarkers. Circulation, 2016, 134, 286-289.	1.6	21
41	Reduced Myocardial Flow in Heart Failure Patients With Preserved Ejection Fraction. Circulation: Heart Failure, 2016, 9, .	1.6	99
42	Applications of 3D printing in cardiovascular diseases. Nature Reviews Cardiology, 2016, 13, 701-718.	6.1	318
43	Unpacking the Black Box: A Formative Research Approach to the Development of Theory-Driven, Evidence-Based, and Culturally Safe Text Messages in Mobile Health Interventions. JMIR MHealth and UHealth, 2016, 4, e10.	1.8	62
44	Technology-Enabled Remote Monitoring and Self-Management “Vision for Patient Empowerment Following Cardiac and Vascular Surgery: User Testing and Randomized Controlled Trial Protocol. JMIR Research Protocols, 2016, 5, e149.	0.5	19
45	I-RREACH: an engagement and assessment tool for improving implementation readiness of researchers, organizations and communities in complex interventions. Implementation Science, 2015, 10, 64.	2.5	35
46	Cancer and Cardiovascular Disease: The Complex Labyrinth. Journal of Oncology, 2015, 2015, 1-2.	0.6	17
47	Metformin increases degradation of phospholamban via autophagy in cardiomyocytes. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, 7165-7170.	3.3	45
48	Role of innate and adaptive immune mechanisms in cardiac injury and repair. Nature Reviews Immunology, 2015, 15, 117-129.	10.6	479
49	HACE1-dependent protein degradation provides cardiac protection in response to haemodynamic stress. Nature Communications, 2014, 5, 3430.	5.8	31
50	Innate Immune Interleukin-1 Receptor-Associated Kinase 4 Exacerbates Viral Myocarditis by Reducing CCR5 <sup>+</sup> CD11b <sup>+</sup> Monocyte Migration and Impairing Interferon Production. Circulation, 2013, 128, 1542-1554.	1.6	43
51	Myocarditis. Lancet, The, 2012, 379, 738-747.	6.3	570
52	Regulatory T Cells Protect Mice Against Coxsackievirus-Induced Myocarditis Through the Transforming Growth Factor $\beta$ 2-Adenovirus Receptor Pathway. Circulation, 2010, 121, 2624-2634.	1.6	115
53	Myeloid Differentiation Factor-88 Plays a Crucial Role in the Pathogenesis of Coxsackievirus B3-Induced Myocarditis and Influences Type I Interferon Production. Circulation, 2005, 112, 2276-2285.	1.6	163
54	Enhanced ERK-1/2 activation in mice susceptible to coxsackievirus-induced myocarditis. Journal of Clinical Investigation, 2002, 109, 1561-1569.	3.9	79

#	ARTICLE	IF	CITATIONS
55	CD45 is a JAK phosphatase and negatively regulates cytokine receptor signalling. Nature, 2001, 409, 349-354.	13.7	501
56	The tyrosine kinase p56lck is essential in coxsackievirus B3-mediated heart disease. Nature Medicine, 2000, 6, 429-434.	15.2	156